NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: AnaSpec, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Launches Industry’s First Assay for Measuring Matriptase Activity - A sensitive, long wavelength fluorimetric assay kit for measuring the activity of Matriptase, a protease implicated in carcinogenesis, is now commercially available - AnaSpec.com
AnaSpec Launches Industry’s First Assay for Measuring Matriptase Activity

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2015/02/11 - A sensitive, long wavelength fluorimetric assay kit for measuring the activity of Matriptase, a protease implicated in carcinogenesis, is now commercially available - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

AnaSpec is pleased to announce the launch of the first commercially available kit for measuring the activity of Matriptase, a protease implicated in carcinogenesis.

The SensoLyte® Rh110 Matriptase Assay Kit provides a convenient assay for screening of Matriptase inhibitors and activators or for continuous assay of Matriptase activity using a highly sensitive fluorogenic substrate. Upon Matriptase cleavage, this substrate generates the Rh110 (Rhodamine 110) fluorophore which has a bright green fluorescence and can be detected at excitation/emission=496 nm/520 nm. The longer wavelength spectra and higher extinction coefficient of Rh110 provide greater sensitivity and less interference from other reaction components. This assay can detect as low as 0.15 ng/mL active Matriptase.

Matriptase (also known as MT-SP1, ST14, TADG-15 and epithin) is a trypsin-like protease from the family of type II transmembrane serine proteases. The spectrum of known Matriptase substrates includes extracellular matrix proteins, cell adhesion molecules, ion channels, growth-factor-like proteins and other proteases. Its actions can result in protein processing, activation or degradation. Matriptase is widely expressed in virtually all epithelium and is specifically found in tumors of epithelial origin. Matriptase has been implicated in carcinogenesis including ovarian, prostate and cervical cancers and is considered a drug target for developing cancer therapeutic agent (1-3).

Reference
1. Welman, A. et al. PLOS One 7, e34182 (2012).
2. List, K. et al. Mol Med 12, 1-3 (2006).
3. Quimbar, P. et al. J Biol Chem 288, 13885 (2013).

About AnaSpec

AnaSpec (anaspec.com), EGT Group is a leading provider of integrated proteomics and genomics solutions™ for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and Takyon™ qPCR MasterMixes. We carry a broad product line of biochemicals and reagents for basic research, high-throughput screening (HTS) and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Launches Industry’s First Assay for Measuring Matriptase Activity

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Cecilia Po - AnaSpec.com 
510-791-9560 cecilia[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering
DSM and the World Food Programme Partner to Improve Nutrition Around the World
European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster
Ipsen Announces Investment in New State-of-the-art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
Veeva Widely Recognized for Leadership and Innovation in Support of Customers and Employees
Veeva Vault CDMS Selected by Idorsia to Modernize Clinical Data Management
Bruker BioSpin Group Introduces New Online Platform to Connect NMR Scientists and Advance NMR Research in Europe
Health Canada Approves Ipsen’s Sohonos (Palovarotene Capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  JobsWare.com





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)